27.7 C
New York
Friday, June 5, 2026

Tag: fertility

newssourceFORcompanyinformationcontent1marketreleases

Fighting the Global Fertility Crisis! Taiwan Pioneers AI-Powered Embryo Selection Model — Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

Breaking Through the "Blind Selection" Dilemma in Clinical Practice — TFC Taipei Fertility Center Introduces AI Scoring System to Help Infertile Couples End the...

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...

Biofertilizer Market worth $6.94 billion by 2031- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

INVO Fertility Announces Second Quarter 2025 Financial Results

SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced second quarter 2025 financial results.

Femasys Announces Second Quarter Financial Results for 2025

-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio --

ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the second quarter of 2025.

SenesTech Reports Second Quarter 2025 Financial Results with Record Revenue and Record Gross Profit Margins

94% Revenue Growth in Evolve™ Rodent Birth Control Products Strong Cash Balance and Sustained Progress Toward Profitability SURPRISE, Ariz., Aug. 7, 2025 /PRNewswire/ -- SenesTech, Inc....

U.S., Japan, and Taiwan Experts Gather at NUWA Forum — Over 200 Reproductive Specialists Explore the Future of Integrated Fertility Technology

Is Increased Use of PGT-A Always Better? Experts Call for Evidence-Based Use of Mosaic EmbryosChoosing the Right PGT-A Platform: NUWA Fertility and Global Experts Unite...

SenesTech Announces Closing of Warrant Exercise for $6.3 Million in Gross Proceeds

SURPRISE, Ariz., Aug. 5, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a leader in fertility control for managing animal pest...

SenesTech Announces Warrant Exercise for $6.3 Million in Gross Proceeds

SURPRISE, Ariz., Aug. 5, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a leader in fertility control for managing animal pest...

How Women Can Tame Medication Costs for the Whole Family

MISSION, Kan., Aug. 4, 2025 /PRNewswire/ -- (Family Features) If you're the one tracking medications, scheduling appointments and making sure the whole household stays...

SenesTech to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern time PHOENIX, July 31, 2025 /PRNewswire/ -- SenesTech, Inc....

COPPER GIANT STRENGTHENS TECHNICAL LEADERSHIP AS MOCOA DRAWS WORLD-CLASS EXPERTISE

Edwin Naranjo Sierra Promoted to VP of Exploration; Mark Gibson Appointed to Board of Directors and Joey Wilkins Joins as Strategic Advisor VANCOUVER, BC, July...

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFertility

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers